Iconic Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2002-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
4
Active:0
Completed:3
Trial Phases
2 Phases
Phase 1:2
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (50.0%)Phase 2
2 (50.0%)Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
Phase 2
Terminated
- Conditions
- Choroidal NeovascularizationWet Macular Degeneration
- First Posted Date
- 2018-03-02
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Iconic Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT03452527
- Locations
- 🇺🇸
Site 2, Beverly Hills, California, United States
🇺🇸Site 8, Santa Ana, California, United States
🇺🇸Site 7, Syracuse, New York, United States
Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma
Phase 1
Completed
- Conditions
- Uveal MelanomaChoroid Neoplasm
- First Posted Date
- 2016-05-13
- Last Posted Date
- 2020-10-01
- Lead Sponsor
- Iconic Therapeutics, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02771340
Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Phase 2
Completed
- Conditions
- Age-related Macular DegenerationChoroidal Neovascularization
- First Posted Date
- 2015-02-09
- Last Posted Date
- 2020-09-24
- Lead Sponsor
- Iconic Therapeutics, Inc.
- Target Recruit Count
- 88
- Registration Number
- NCT02358889
Safety and Tolerability Study for Age-Related Macular Degeneration
Phase 1
Completed
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- Drug: hI-con1™ 150µlDrug: hI-con1™ 300µlDrug: hI-con1™ 60µl
- First Posted Date
- 2011-12-05
- Last Posted Date
- 2020-11-06
- Lead Sponsor
- Iconic Therapeutics, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT01485588
- Locations
- 🇺🇸
Rocky Mountain Eye Center, P.C., Missoula, Montana, United States
🇺🇸Retina & Vitreous Center of Southern Oregon, P.C., Ashland, Oregon, United States
🇺🇸Palmetto Retina Center, West Columbia, South Carolina, United States
News
No news found